The Global Radiotherapy Market is poised to grow strong during the forecast period 2017 to 2025.
Some of the prominent trends that the market is witnessing include Intensity Modulated Radiotherapy (IMRT) and image guided brachytherapy (IGBT) are the recent advancements, Artificial Neural Networks (ANN) to predict complications after radiotherapy, in prostate cancer, increasing IMRT utilization after metastatic cancer diagnosis and chemo-radiotherapy with a new radiosensitizer infusion by endoscopic guide.
Based on Product, market is divided into Systemic Radiotherapy, Internal Beam Radiotherapy/Brachytherapy and External Beam Radiotherapy. Systemic Radiotherapy is further classified into Samarium-153, Rhenium-186, Iobenguane (I-131) and Other Systemic Radiotherapy Products.
Internal Beam Radiotherapy/Brachytherapy segment is sub divided into electronic brachytherapy products, applicators and afterloaders and seeds. External Beam Radiotherapy segment is sub divided into proton therapy systems, compact advanced radiotherapy devices and electron-emitting high-energy linear accelerators (Linac).
By Technology, market is classified into internal beam radio therapy, systemic radiation therapy and external beam radiation therapy. Internal Beam Radio Therapy is further segmented into high dose rate and low dose rate.
Systemic Radiation Therapy segment is sub divided into oral radiotherapy, intravenous radiotherapy and instillation radiotherapy. External Beam Radiation Therapy market is sub fragmented into intensity modulated radiotherapy (IMRT), tomotherapy, 3D Conformal Radiotherapy (3D CRT), image-guided radiotherapy (IGRT), volumetric modulated arc therapy (VMAT), stereotactic technology, proton beam therapy and adaptive radiation therapy.
Based on Application, the market is segmented into breast cancer, esophageal cancer, head & neck cancer, penile cancer, skin & lip cancer, gynecological cancer, prostate cancer, colorectal cancer, lung cancer, brain cancer, cervical cancer and spine cancer.
By End User, market is categorized into Hospitals & Clinics, Ambulatory & Radiotherapy Centers and Cancer Research Institutes.
This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2014, 2015 revenue estimations are presented for 2016 and forecasts from 2017 till 2025.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc. The market data is gathered from extensive primary interviews and secondary research.
The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.
This report provides data tables, includes charts and graphs for visual analysis.
Regional Analysis: • North America o US o Canada o Mexico • Europe o Germany o U.K o France o Italy o Spain o Rest of Europe • Asia Pacific o China o Japan o India o Australia o New Zealand o Rest of Asia Pacific • Middle East o Saudi Arabia o UAE o Rest of Middle East • Latin America o Argentina o Brazil o Rest of Latin America • Rest of the World o South Africa o Others
Report Highlights: - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments
Our reports have been used by over 10K customers, including:
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 126.96.36.199) - Pipeline Review, H2 2018 Summary According to the recently published report ’RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2018’;...
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 188.8.131.52) - Pipeline Review, H2 2018 Summary According to the recently published report ’Tyrosine Protein Kinase Fyn - Pipeline Review, H2 2018’; Tyrosine Protein Kinase Fyn (Proto Oncogene...
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or...
Cancer Pain - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2018, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape. Cancer pain can be defined as a complex...
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2018 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family,...
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2018 Summary Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T...
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2018, provides an overview of the Post-Polycythemia Vera Myelofibrosis...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.